The 4G/5G polymorphism in the PAI-1 inhibitor gene - Mbarek, Lamia
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
16 °P sammeln
  • Broschiertes Buch

SUMMARY Cerebral venous thrombosis (CVT) disease is a rare but serious pathology. It is a multifactorial disease, resulting from the combination of several risk factors. This case-control study aims to explore the impact of the -675 4G/5G polymorphism of the PAI-1 gene on CVT disease in the young Tunisian population. 30 patients with CVT and 60 controls were recruited for this study. DNA was isolated from whole blood and genotyping of the -675 4G/5G polymorphism of PAI-1 was performed by PCR-AS technique. The risk of association was estimated by calculating the odds ratio (OR) with a 95%…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
SUMMARY Cerebral venous thrombosis (CVT) disease is a rare but serious pathology. It is a multifactorial disease, resulting from the combination of several risk factors. This case-control study aims to explore the impact of the -675 4G/5G polymorphism of the PAI-1 gene on CVT disease in the young Tunisian population. 30 patients with CVT and 60 controls were recruited for this study. DNA was isolated from whole blood and genotyping of the -675 4G/5G polymorphism of PAI-1 was performed by PCR-AS technique. The risk of association was estimated by calculating the odds ratio (OR) with a 95% confidence interval.The mean age of patients was 36.97 ± 8.231 years and33, 80± 8.517years in controls, with a female predominance (63% vs 37%). The frequency of PAI-1 genotypes in 25% 5G/5G; 62%4G/5G; 13%4G/4G in patients compared with 23% 5G/5G; 40%4G/5G; 37%4G/4G in controls. The homozygous 4G/4G genotype was significantly associated with an increased risk of stroke occurrence (OR: 2.444, CI95% [1.101-5.676]; p: 0.020).In conclusion, the study we conducted confirms that the -675 4G/5G polymorphism of
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dra. Lamia Mbarek Laboratório de Neurogenética, Doença de Parkinson e Doença Cerebrovascular (LR-12-SP-19); Hospital Universitário Habib Bourguiba, Universidade de Sfax, Tunísia Centro de Investigação Clínica (CIC), Hospital Universitário Habib Bourguiba, Tunísia